http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021, reinforcing long-standing commitment to advancing epilepsy treatment and care
-
UCB Announces Global Partnership To Bring Disease-Modifying Therapies To People Living With Parkinson's Disease
-
Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms
-
UCB Showcases Key Rheumatology Data at ACR Convergence 2021
-
Sharecare and UCB to present on future of decentralized clinical research at 2021 CNS Summit
-
Unique Patient-led and Co-authored Analysis of the Experience of Living with Myasthenia Gravis Published in Neurology and Therapy
-
UCB to license its AI technology that improves identification of Osteoporosis to ImageBiopsy Lab
-
Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab
-
New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress
-
ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19
-
UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older
-
ExeVir announces first subjects dosed in Phase I clinical study of potent COVID-19 neutralizing antibody
-
New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis
-
M8 Pharmaceuticals and UCB partner for Central Nervous System and Respiratory Portfolio in Mexico
-
Neuropore Therapies Receives $20 Million (USD) Milestone Payment Under Collaboration and License Agreement with UCB
-
"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis
-
UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021
-
UCB showcases new research at the 73rd American Academy of Neurology Annual Meeting to demonstrate broad neurology leadership and future portfolio
-
ExeVir Announces Close of US$50 million / EUR42 million Series A Financing
-
UCB Full Year Report 2020: UCB - sustaining growth, now and into the future
-
UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development
-
UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development
-
UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy
-
UCB Demonstrates Commitment to Science and Discovery Across Its Epilepsy Portfolio at the American Epilepsy Society's Virtual Event AES2020
-
Specifica Delivers Antibody Platform to UCB to Speed up Development of New Therapeutics
-
World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19
-
UCB taps Medisafe in development of digital companion to support patient engagement
-
UCB's VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy
-
UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms
-
UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020
-
Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira® in Moderate-to-Severe Psoriasis Patients
-
UCB Presents Nine Abstracts at EADV 2020, Showcasing Ongoing Commitment to Dermatology
-
UCB and Aetion Announce Agreement to Enhance Real-World Evidence Generation to Advance Value-Based Contracts
-
UCB Achieves Important Regulatory Milestone for Bimekizumab
-
Tennis Champion Caroline Wozniacki and UCB Launch Advantage Hers Campaign for Women with Chronic Inflammatory Diseases
-
Phase 3 data on VIMPAT® (lacosamide) CV in primary generalized tonic-clonic seizures published in Journal of Neurology, Neurosurgery & Psychiatry
-
UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer's Disease
-
ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against COVID-19
-
UCB Half Year Report 2020
-
Bimekizumab Superior to Cosentyx® in Achieving Complete Psoriasis Skin Clearance
-
UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA® (certolizumab pegol) for the Treatment of Adults with Moderate to Severe Crohn's Disease
-
UCB Announces New Data from its Epilepsy Portfolio Presented on the American Academy of Neurology Virtual Platform
-
New Capture the Fracture® Partnership Aims for 25% Reduction in the Incidence of Hip and Vertebral Fractures Due to Osteoporosis by 2025
-
First Presentations of Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara® at Week 16 in Adults with Moderate-to-Severe Plaque Psoriasis
-
UCB Acquires Engage Therapeutics: Staccato® Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy
-
UCB's General Meeting of Shareholders
-
UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients
-
UCB Full Year Report 2019
-
UCB and Accenture Collaborate to Accelerate Data Processing and Help Improve Patient Safety
-
Amgen (AMGN), UCB Announce EC Approves EVENITY for Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture
